Literature DB >> 15307169

Frontline: absence of functional STAT4 activation despite detectable tyrosine phosphorylation induced by murine IFN-alpha.

Lisa S Berenson1, J David Farrar, Theresa L Murphy, Kenneth M Murphy.   

Abstract

We previously reported that IL-12, but not IFN-alphaA/D, induces T helper type (Th) 1 development and STAT4 phosphorylation in murine CD4+ T cells. However, a recent study reported that IFN-alphaA/D and recombinant murine IFN-alphaA can induce STAT4 phosphorylation, although more weakly than IL-12, largely in CD8+ rather than CD4+ T cells. That report did not examine Th1 development or directly demonstrate induction of IFN-gamma by IFN-alpha. To address these differences, we compared IFN-alphaA/D, murine IFN-alphaA, and IL-12 for STAT4 phosphorylation, formation of active nuclear DNA binding complexes, induction of Th1 development, and production of IFN-gamma in murine CD4+ T cells. IFN-alphaA induced detectable STAT4 phosphorylation, although at significantly lower levels than induced by IL-12. Furthermore, in contrast to IL-12, IFN-alphaA failed to induce Th1 development or the formation of DNA binding complexes or to synergize with IL-18 for induction of IFN-gamma production. STAT1-deficient CD4+ T cells showed increased IFN-alphaA-induced STAT4 phosphorylation but still exhibited significantly lower amounts of cytokine-induced IFN-gamma compared to IL-12. In summary, these results suggest that in contrast to IL-12, IFN-alphaA does not play a functionally significant role in meditating the STAT4-dependent induction of Th1 development or IFN-gamma production in CD4+ T cells. Copyright 2004 Wiley-VCH Verlag GmbH & Co.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307169     DOI: 10.1002/eji.200324829

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Fate vs choice: the immune system reloaded.

Authors:  Kenneth M Murphy
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression.

Authors:  Hilario J Ramos; Ann M Davis; Thaddeus C George; J David Farrar
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 3.  Regulation of effector and memory T-cell functions by type I interferon.

Authors:  Jonathan P Huber; J David Farrar
Journal:  Immunology       Date:  2011-02-14       Impact factor: 7.397

4.  Type I IFN induces binding of STAT1 to Bcl6: divergent roles of STAT family transcription factors in the T follicular helper cell genetic program.

Authors:  Shingo Nakayamada; Amanda C Poholek; Kristina T Lu; Hayato Takahashi; Masanari Kato; Shigeru Iwata; Kiyoshi Hirahara; Jennifer L Cannons; Pamela L Schwartzberg; Golnaz Vahedi; Hong-Wei Sun; Yuka Kanno; John J O'Shea
Journal:  J Immunol       Date:  2014-01-31       Impact factor: 5.422

Review 5.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

6.  Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain.

Authors:  Douglas R Tyler; Meredith E Persky; Loderick A Matthews; Sheuwen Chan; J David Farrar
Journal:  Mol Immunol       Date:  2006-11-13       Impact factor: 4.407

7.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

Review 8.  STAT2: A shape-shifting anti-viral super STAT.

Authors:  Fatema Z Chowdhury; J David Farrar
Journal:  JAKSTAT       Date:  2013-01-01

9.  Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infection.

Authors:  Ethan A Mack; Lara E Kallal; Delia A Demers; Christine A Biron
Journal:  MBio       Date:  2011-08-09       Impact factor: 7.867

10.  Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.

Authors:  Philippe Fournier; Volker Schirrmacher
Journal:  Biology (Basel)       Date:  2013-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.